Bank of New York Mellon’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $414K | Buy |
62,750
+19,606
| +45% | +$134K | ﹤0.01% | 3843 |
|
|
2026
Q1 | $301K | Buy |
43,144
+1,941
| +5% | +$15.1K | ﹤0.01% | 3854 |
|
|
2025
Q4 | $291K | Buy |
41,203
+16,805
| +69% | +$130K | ﹤0.01% | 3878 |
|
|
2025
Q3 | $182K | Buy |
24,398
+409
| +2% | +$3.11K | ﹤0.01% | 4042 |
|
|
2025
Q2 | $176K | Buy |
23,989
+7,497
| +45% | +$65.4K | ﹤0.01% | 4020 |
|
|
2025
Q1 | $127K | Buy |
16,492
+2,596
| +19% | +$28.5K | ﹤0.01% | 3969 |
|
|
2024
Q4 | $168K | Buy |
13,896
+1,389
| +11% | +$17.8K | ﹤0.01% | 3984 |
|
|
2024
Q3 | $157K | Sell |
12,507
-5,759
| -32% | -$74.3K | ﹤0.01% | 3954 |
|
|
2024
Q2 | $218K | Buy |
+18,266
| New | +$251K | ﹤0.01% | 3921 |
|
|
2023
Q2 | – | Sell |
-13,376
| Closed | -$41.5K | – | 4422 |
|
|
2023
Q1 | $41.5K | Sell |
13,376
-13,376
| -50% | -$50.8K | ﹤0.01% | 4222 |
|
|
2022
Q4 | $106K | Sell |
26,752
-201
| -0.7% | -$820 | ﹤0.01% | 4104 |
|
|
2022
Q3 | $102K | Hold |
26,953
| – | – | ﹤0.01% | 4192 |
|
|
2022
Q2 | $360K | Sell |
26,953
-1,955
| -7% | -$13K | ﹤0.01% | 3783 |
|
|
2022
Q1 | $143K | Buy |
28,908
+18,867
| +188% | +$93.5K | ﹤0.01% | 4333 |
|
|
2021
Q4 | $69K | Hold |
10,041
| – | – | ﹤0.01% | 4456 |
|
|
2021
Q3 | $309K | Hold |
10,041
| – | – | ﹤0.01% | 4025 |
|
|
2021
Q2 | $326K | Sell |
10,041
-8,153
| -45% | -$280K | ﹤0.01% | 3937 |
|
|
2021
Q1 | $688K | Buy |
18,194
+7,504
| +70% | +$343K | ﹤0.01% | 3525 |
|
|
2020
Q4 | $506K | Buy |
10,690
+226
| +2% | +$9.79K | ﹤0.01% | 3612 |
|
|
2020
Q3 | $337K | Buy |
10,464
+958
| +10% | +$37.5K | ﹤0.01% | 3671 |
|
|
2020
Q2 | $419K | Buy |
9,506
+6,053
| +175% | +$284K | ﹤0.01% | 3562 |
|
|
2020
Q1 | $113K | Sell |
3,453
-32
| -0.9% | -$1.47K | ﹤0.01% | 3841 |
|
|
2019
Q4 | $178K | Hold |
3,485
| – | – | ﹤0.01% | 3945 |
|
|
2019
Q3 | $128K | Hold |
3,485
| – | – | ﹤0.01% | 3989 |
|
|
2019
Q2 | $192K | Sell |
3,485
-4,266
| -55% | -$267K | ﹤0.01% | 3934 |
|
|
2019
Q1 | $472K | Sell |
7,751
-335
| -4% | -$21.5K | ﹤0.01% | 3584 |
|
|
2018
Q4 | $478K | Sell |
8,086
-1,742
| -18% | -$128K | ﹤0.01% | 3511 |
|
|
2018
Q3 | $794K | Buy |
9,828
+2,120
| +28% | +$168K | ﹤0.01% | 3400 |
|
|
2018
Q2 | $675K | Buy |
7,708
+3,577
| +87% | +$627K | ﹤0.01% | 3468 |
|
|
2018
Q1 | $799K | Buy |
4,131
+1,198
| +41% | +$223K | ﹤0.01% | 3335 |
|
|
2017
Q4 | $300K | Sell |
2,933
-9
| -0.3% | -$459 | ﹤0.01% | 3798 |
|
|
2017
Q3 | $111K | Sell |
2,942
-110
| -4% | -$3.3K | ﹤0.01% | 3994 |
|
|
2017
Q2 | $107K | Buy |
+3,052
| New | +$110K | ﹤0.01% | 4014 |
|
|
2017
Q1 | – | Sell |
-154
| Closed | -$11K | – | 4297 |
|
|
2016
Q4 | $11K | Sell |
154
-2
| -1% | -$180 | ﹤0.01% | 4242 |
|
|
2016
Q3 | $21K | Sell |
156
-34
| -18% | -$5.13K | ﹤0.01% | 4214 |
|
|
2016
Q2 | $32K | Buy |
190
+26
| +16% | +$4.43K | ﹤0.01% | 4237 |
|
|
2016
Q1 | $31K | Hold |
164
| – | – | ﹤0.01% | 4137 |
|
|
2015
Q4 | $58K | Sell |
164
-1
| -0.6% | -$393 | ﹤0.01% | 4159 |
|
|
2015
Q3 | $86K | Buy |
165
+1
| +0.6% | +$1.52K | ﹤0.01% | 4143 |
|
|
2015
Q2 | $362K | Buy |
164
+6
| +4% | +$12K | ﹤0.01% | 3730 |
|
|
2015
Q1 | $369K | Hold |
158
| – | – | ﹤0.01% | 3720 |
|
|
2014
Q4 | $327K | Hold |
158
| – | – | ﹤0.01% | 3755 |
|
|
2014
Q3 | $314K | Hold |
158
| – | – | ﹤0.01% | 3772 |
|
|
2014
Q2 | $560K | Sell |
158
-141
| -47% | -$460K | ﹤0.01% | 3573 |
|
|
2014
Q1 | $1.12M | Sell |
299
-3
| -1% | -$11.1K | ﹤0.01% | 3215 |
|
|
2013
Q4 | $988K | Buy |
302
+30
| +11% | +$118K | ﹤0.01% | 3316 |
|
|
2013
Q3 | $1.14M | Buy |
272
+71
| +35% | +$286K | ﹤0.01% | 3168 |
|
|
2013
Q2 | $675K | Buy |
+201
| New | +$765K | ﹤0.01% | 3381 |
|
Other funds holding GYRE
SS
SO
N
PFSRSONJ
Bank of New York Mellon's GYRE Position: Q2 2026 in Review
Bank of New York Mellon increased its Gyre Therapeutics (GYRE) stake by 45% in Q2 2026, buying an estimated $134K and bringing the position to 62,750 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #3843.
Bank of New York Mellon first reported a position in GYRE in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.14M in Q3 2013. 30 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.
- Bank of New York Mellon held 62,750 shares of Gyre Therapeutics worth $414K as of Q2 2026.
- Bank of New York Mellon bought 19,606 Gyre Therapeutics shares in Q2 2026, an estimated $134K.
- Gyre Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3843 holding.
- Bank of New York Mellon first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 48 quarters since.
- Bank of New York Mellon's Gyre Therapeutics position peaked at $1.14M in Q3 2013.
- 30 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.